Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
AssigneeArgos Therapeutics, Inc.
InventorsAlexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
Life of this patent
Estimating the term…
Abstract
The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
Claims25
1-28. (canceled)
A monomeric soluble form of a member of the CD83 family of proteins (monomeric CD83 protein), wherein one or more cysteine residues are substituted with a small and/or polar amino acid residue.
Dependencies are inferred from the claim text.